LYPD3: An Emerging Star in Solid Tumor Therapy1. Overview of LYPD3
LYPD3 (Ly6/PLAUR Domain-Containing Protein 3), also known as C4.4A, is a glycosylphosphatidylinositol (GPI)-anchored cell membrane protein that plays a key role in tumor progression,... Detailed information
Immune Battlefield's "Scout": Decoding the NCR3 TargetThe global tumor immunotherapy market is expected to exceed $200 billion by 2025, and NCR3, as a key "switch" for NK cell activation, has become a highly sought-after target for pharmaceutical companies. Multinational dr... Detailed information